arrow
J

Jaime Feliú

Hospital Universitario La Paz
H指数:44
被引数:7,249

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Studying When to Add Biological Therapy to Cytotoxic Therapy in Advanced Cancer Care Using Real World Data: How to Avoid Design Choices That Generate Immortal Time

利用真实世界数据研究在晚期癌症护理中何时将生物疗法添加到细胞毒性疗法中:如何避免产生不归者时间的设计选择

2026-06-190
OAAI
Proteomic Analysis of Paired FFPE Tissue and Extracellular Vesicles Reveals Proteins Associated with Recurrence in Stage II Colorectal Cancer

配对FFPE组织和细胞外囊泡的蛋白质组学分析揭示了与II期结直肠癌复发相关的蛋白质

2026-04-120
OA
CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1

CD40激动剂米他扎利单抗联合mFOLFIRINOX治疗未治疗转移性胰腺癌:OPTIMIZE-1研究中与结局相关的生物标志物

2025-10-070
OAAI
DPYD-guided fluoropyrimidine dose adjustment in colorectal cancer DPYD carriers: start slower to finish stronger

DPYD指导下的氟嘧啶剂量调整在携带DPYD的结直肠癌患者中的应用:慢速起始,强力结束

2025-09-210
OAAI
Analysis of tumor budding as a prognostic factor for recurrence in patients with stage II and III colon cancer. Experience in a tertiary hospital

肿瘤簇分析作为II期和III期结肠癌患者复发的预后因素。一家三级医院的经验

2025-03-010
OAAI
CD40 agonist mitazalimab combined with mFOLFIRINOX (mFFX) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Primary analysis of the OPTIMIZE-1 phase Ib/II study
2024-06-010
PRE
CD40 agonist mitazalimab in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Interim efficacy results of the OPTIMIZE-1 phase 1b/2 study
2024-01-160
PRE
First-line chemotherapy with or without targeted therapies in metastatic colorectal cancer: The GEMCAD 14-01 prospective cohort
2023-10-010
PRE